Abstract
1,4-Dihydropyridines are well-known calcium channel blockers, but variations in the substituents attached to the ring have resulted in their role reversal making them calcium channel activators in some cases. We describe the microwave-assisted eco-friendly approach for the synthesis of pyranopyrazole-1,4-dihydropyridines, a new class of 1,4-DHPs, under solvent-free conditions in good yield, and screen them for various in silico, in vitro and in vivo activities. The in vivo experimentation results show that the compounds possess positive inotropic effect, and the docking results validate their good binding with calcium channels. Compounds 7c, 7g and 7i appear to be the most effective positive inotropes, even at low doses, and bind with the calcium channels even more strongly than Bay K 8644, a well-known calcium channel activator. The chronotropic effect for the new compounds was also studied. The target and off-target affinity profiling supported the in vivo results and revealed that the hybridized pyranopyrazole dihydropyridine scaffold has delivered new moderate hits, to be optimized, for the cytochrome P450 3A4 enzymes, opening avenues for combined pharmacological activity through standard structural modification.
Graphical Abstract
Similar content being viewed by others
References
Carafoli E, Klee C (1999) Calcium as cellular regulator. Oxford University Press, New York, pp 171–200
William JE, Venkata CSR (2011) Calcium channel blockers. J Clin Hypertens 13:687–689. doi:10.1111/j.1751-7176.2011.00513
Bossert F, Meyer H, Wehinger E (1981) 4-Aryldihydropyridines, a new class of highly active calcium antagonists. Angew Chem Int Edit 20:762–769. doi:10.1002/anie.198107621
Sohal HS, Goyal A, Sharma R, Khare R (2014) One-pot multicomponent synthesis of symmetrical Hantzsch 1,4-dihydropyridine derivatives using glycerol as clean and green solvent. Eur J Med Chem 5:171–175. doi:10.5155/eurjchem.5.1.171-175.943
Ali HI, Ashida N, Nagamatsu T (2007) Design, synthesis, antitumor activity, and molecular docking study of novel 2-methylthio-, 2-amino-, and 2-(\(N\)-substituted amino)-10-alkyl-2-deoxo-5-deazaflavins. Bioorg Med Chem 15:6336–6352. doi:10.1016/j.bmc.2007.06.058
Pavani MG, Nunez M, Brigidi P, Vitali B, Gambari R (2002) Antimicrobial and antitumor activity of \(N\)-heteroimmine-1,2,3-dithiazoles and their transformation in triazolo-, imidazo-, and pyrazolopirimidines. Bioorg Med Chem 10:449–456. doi:10.1016/S0968-0896(01)00294-2
Sondhi SM, Johar M, Rajvanshi S, Dastidar SG, Shukla R, Raghubir R, Lown JW (2001) Anticancer, anti-inflammatory and analgesic activity evaluation of heterocyclic compounds synthesized by the reaction of 4-isothiocyanato-4-methylpentan-2-one with substituted \(o\)-phenylenediamines, \(o\)-diaminopyridine and (Un)substituted. Aust J Chem 54:69–74. doi:10.1071/CH00141
Narayana LB, Rao RRA, Rao SP (2009) Synthesis of new 2-substituted pyrido[2,3-\(d\)]pyrimidin-4(1H)-ones and their antibacterial activity. Eur J Med Chem 44:1369–1376. doi:10.1016/j.ejmech.2008.05.025
Trivedi A, Dodiya D, Dholariya B, Kataria V, Bhuva V, Shah V (2011) Synthesis and biological evaluation of some novel 1,4-dihydropyridines as potential antitubercular agents. Chem Biol Drug Des 78:881–886. doi:10.1111/j.1747-0285.2011.01233.x
Shishoo CJ, Shirsath VS, Rathod IS, Patil MJ, Bhargava SS (2001) Design, synthesis and antihistaminic (H1) activity of some condensed 2-(substituted) arylaminoethylpyrimidine-4-(3\(H\))-ones. Arzneim Forsch 51:221–231
Jiang J, Rhee MA, Melman N, Ji X, Jacobson KA (2006) 6-Phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 39:4667–4675. doi:10.1021/jm960457c
Li AH, Chang L, Ji X, Melman N, Jacobson KA (2009) Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors. Bioconjug Chem 10:667–677. doi:10.1021/bc9900136
Bakali JE, Gilleron P, Malapel MB, Mansouri R, Muccioli GG, Djouina M, Barczyk A, Klupsch F, Andrzejak V, Lipka E, Furman C, Lambert DM, Chavatte P, Desreumaux P, Millet R (2012) 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: Discovery of new agonists endowed with protective effect against experimental colitis. J Med Chem 55:8948–8952. doi:10.1021/jm3008568
Nantermet PG, Barrow JC, Selnick HG, Homnick CF, Freidinger RM, Chang RS, O’Malley SS, Reiss DR, Broten TP, Ransom RW, Pettibone DJ, Olah T, Forray C (2000) Selective \(\upalpha \)1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones. Bioorg Med Chem Lett 10:1625–1628. doi:10.1016/S0960-894X(99)00696-4
Niwa T, Shiraga T, Hashimoto T, Kagayama A (2004) Effect of Nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 27:415–417. doi:10.1248/bpb.27.415
Viegas-Junior C, Danuello A, Silva DBV, Barreiro EJ, Fraga CA (2007) Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 14:1829–1829. doi:10.2174/092986707781058805
Huang LJ, Hour MJ, Teng CM, Kuo SC (1992) Synthesis and antiplatelet activities of \(N\)-arylmethyl-3,4-dimethylpyrano[2,3-\(c\)]pyrazol-6-one derivatives. Chem Pharm Bull 40:2547–2551
Mohamed NR, Khaireldin NY, Fahmyb AF, El-Sayeda AAF (2010) Facile synthesis of fused nitrogen containing heterocycles as anticancer agents. Der Pharm Chem 2:400–417
Ueda T, Mase H, Oda N, Ito I (1981) Synthesis of pyrazolone derivatives. XXXIX. Synthesis and analgesic activity of pyrano[2,3-\(c\)]pyrazoles. Chem Pharm Bull 29:3522–3528. doi:10.1248/cpb.29.3522
Kuo SC, Huang LJ, Nakamura H (1984) Synthesis and analgesic and antiinflammatory activities of 3,4-dimethylpyrano[2,3-\(c\)]pyrazol-6-one derivatives. J Med Chem 27:539–544. doi:10.1021/jm00370a020
Assiery SE, Sayed GH, Fouda A (2004) Synthesis of some new annulated pyrazolo-pyrido (or pyrano) pyrimidine, pyrazolopyridine and pyranopyrazole derivatives. Acta Pharma 54:143–150
Mohammad MM, Mohammad RJ, Mohammad B (2006) Facile synthesis of pyrano[2,3-\(c\)]pyrazol-6-one derivatives under microwave irradiation in solvent-free conditions. Synth Comm 36:51–58. doi:10.1080/00397910500328886
Noda M, Shimizu S, Tanabe T, Takai T, Kayano T, Ikeda T, Takahashi H, Nakayama H, Kanaoka Y, Minamino N (1984) Primary structure of electrophorus electricus sodium channel deduced from cDNA sequence. Nature 312:121–127. doi:10.1038/312121a0
Tanabe T, Takeshima H, Mikami A, Flockerzi V, Takahashi H, Kanqawa A, Kojima M, Matsuo H, Hirose T, Numa S (1987) Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature 328:313–318. doi:10.1038/328313a0
Tempel BL, Papazian DM, Schwarz TL, Jan LY, Jan YN (1987) Sequence of a probable potassium channel component encoded at Shaker locus of Drosophila. Science 237:770–775. doi:10.1126/science.2441471
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. doi:10.1021/jm0306430
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750–1759. doi:10.1021/jm030644s
Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49(2):377–389. doi:10.1021/ci800324m
Tikhonov DB, Zhorov BS (2005) Modeling P-loops domain of sodium channel: homology with potassium channels and interaction with ligands. Biophys J 88:184–197. doi:10.1529/biophysj.104.048173
Tikhonov DB, Zhorov BS (2008) Molecular modeling of benzothiazepine binding in the L-type calcium channel. J Biol Chem 283:17594–17604. doi:10.1074/jbc.M800141200
Yamaguchi S, Zhorov BS, Yoshioka K, Nagao T, Ichijo H, Adachi-Akahane S (2003) Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5–S6 linker of L-type Ca\(^{2+}\) channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca\(^{2+}\) channel agonists. Mol Pharmacol 64:235–248. doi:10.1124/mol.64.2.235
Vidal D, Garcia-Serna R, Mestres J (2011) Ligand-based approaches to in silico pharmacology. Methods Mol Biol 672:489–502. doi:10.1007/978-1-60761-839-3_19
Garcia-Serna R, Vidal D, Remez N, Mestres J (2015) Large-scale predictive drug safety: from structural alerts to biological mechanisms. Chem Res Toxicol 28:1875–1887. doi:10.1021/acs.chemrestox.5b00260
Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, Davies M, Dedman N, Karlsson A, Magariños MP, Overington JP, Papadatos G, Smit I, Leach AR (2017) The ChEMBL database in 2017. Nucleic Acids Res 45:D945–D954. doi:10.1093/nar/gkw1074
Matsui T, Takeuchi M, Yamagishi S (2010) Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 396:566–570. doi:10.1016/j.bbrc.2010.04.149
Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225–11236. doi:10.1021/ja9621760
SiteMap (2009) version 2.3, Schrödinger. LLC, New York, NY
Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25:197–206. doi:10.1038/nbt1284
Briansó F, Carrascosa MC, Oprea TI, Mestres J (2011) Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem 11:1956–1963. doi:10.2174/156802611796391285
Areias FM, Brea J, Gregori-Puigjané E, Zaki MEA, Carvalho MA, Domínguez E, Gutiérrez-de-Terán H, Proença MF, Loza MI, Mestres J (2010) In silico directed chemical probing of the adenosine receptor family. Bioorg Med Chem 18:3043–3052. doi:10.1016/j.bmc.2010.03.048
Mestres J, Seifert SA, Oprea TI (2011) Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther 90:662–665. doi:10.1038/clpt.2011.177
Antolín AA, Jalencas X, Yélamos J, Mestres J (2012) Identification of PIM kinases as novel targets for PJ34 with confounding effects in PARP biology. ACS Chem Biol 7:1962–1967. doi:10.1021/cb300317y
Antolín AA, Mestres J (2015) Distant polypharmacology among MLP chemical probes. ACS Chem Biol 10:395–400. doi:10.1021/cb500393m
Montolio M, Gregori-Puigjané E, Pineda D, Mestres J, Navarro P (2012) Identification of small molecule inhibitors of amyloid \(\upbeta \)-induced neuronal apoptosis acting through the imidazoline I(2) receptor. J Med Chem 55:9838–9846. doi:10.1021/jm301055g
Waller CL, Juma BW, Gray LE Jr, Kelce WR (1996) Three-dimensional quantitative structure-activity relationships for androgen receptor ligands. Toxicol Appl Pharmacol 137:219–227. doi:10.1006/taap.1996.0075
Stefanachi A, Nicolotti O, Leonetti F, Cellamare S, Campagna F, Loza MI, Brea JM, Mazza F, Gavuzzo E, Carotti A (2008) 1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships. Bioorg Med Chem 16:9780–9789. doi:10.1016/j.bmc.2008.09.067
Acknowledgements
This work was partially supported by ChemBiobank, the Chemical Biology infrastructure initiative in Spain, carrying out the predictive and the biological activity of the synthesized compounds. The authors would like to thank CDRI, Lucknow, for carrying out the in vivo studies, Defence Research and Development Organization (DRDO) for financial support and University of Delhi, Delhi, for providing the laboratory and instrumentation facility.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
11030_2017_9738_MOESM1_ESM.docx
Supplementary Data Supplementary data (1H NMR, 13C NMR spectra and UPLC-MS results) associated with this article can be found. (doc 5.98MB)
Rights and permissions
About this article
Cite this article
Kumar, R., Yadav, N., Lavilla, R. et al. Synthesis, pharmacological evaluation and molecular docking of pyranopyrazole-linked 1,4-dihydropyridines as potent positive inotropes. Mol Divers 21, 533–546 (2017). https://doi.org/10.1007/s11030-017-9738-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-017-9738-7